-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – DNTH-103 in Multifocal Motor Neuropathy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - DNTH-103 in Multifocal Motor Neuropathy report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. DNTH-103 in Multifocal Motor Neuropathy Drug Details: DNTH-103 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – DNTH-103 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - DNTH-103 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. DNTH-103 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Drug...
-
Product Insights
Multifocal Motor Neuropathy – Drugs In Development, 2023
Global Markets Direct’s, ‘Multifocal Motor Neuropathy - Drugs In Development, 2023’, provides an overview of the Multifocal Motor Neuropathy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Multifocal Motor Neuropathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) – Drugs In Development, 2023
Global Markets Direct’s, ‘Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Drugs In Development, 2023’, provides an overview of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Peripheral Neuropathy (Sensory Neuropathy) – Drugs In Development, 2023
Global Markets Direct’s, ‘Peripheral Neuropathy (Sensory Neuropathy) - Drugs In Development, 2023’, provides an overview of the Peripheral Neuropathy (Sensory Neuropathy) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Peripheral Neuropathy (Sensory Neuropathy), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Myasthenia Gravis – Drugs In Development, 2023
Global Markets Direct’s, ‘Myasthenia Gravis - Drugs In Development, 2023’, provides an overview of the Myasthenia Gravis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Myasthenia Gravis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Neuropathy – Drugs In Development, 2023
Global Markets Direct’s, ‘Neuropathy - Drugs In Development, 2023’, provides an overview of the Neuropathy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Neuropathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Acquired (Autoimmune) Hemolytic Anemia – Drugs In Development, 2023
Global Markets Direct’s, ‘Acquired (Autoimmune) Hemolytic Anemia - Drugs In Development, 2023’, provides an overview of the Acquired (Autoimmune) Hemolytic Anemia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Acquired (Autoimmune) Hemolytic Anemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – INNA-051 in Influenza A Virus, H3N2 Subtype Infections
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.INNA-051 in Influenza A Virus, H3N2 Subtype Infections Drug Details: INNA-051 (INNA-X) is under development for...